RBC
BIO icon

Romano Brothers & Co’s Bio-Rad Laboratories Class A BIO Stock Holding History

Romano Brothers & Co’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-102
Closed -$42.9K – 369
2022
Q4 		$42.9K Buy
+102
New +$41.2K 0.01% 496

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Romano Brothers & Co's BIO Position: Q1 2023 in Review

Romano Brothers & Co sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2023, closing a stake of 102 shares — an estimated $42.9K sold.

Romano Brothers & Co first reported a position in BIO in Q4 2022 and held it in 1 quarter. The position peaked at $42.9K in Q4 2022. 505 funds tracked by Wall St. Rank hold BIO as of Q1 2023.

  • Romano Brothers & Co reported no remaining Bio-Rad Laboratories Class A position as of Q1 2023 after selling out during the quarter.
  • Romano Brothers & Co sold 102 Bio-Rad Laboratories Class A shares in Q1 2023, an estimated $42.9K.
  • Romano Brothers & Co first reported a position in Bio-Rad Laboratories Class A in Q4 2022 and held it in 1 quarter.
  • Romano Brothers & Co's Bio-Rad Laboratories Class A position peaked at $42.9K in Q4 2022.
  • 505 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2023.

Based on Romano Brothers & Co's 13F filing for Q1 2023, filed 13 Apr 2023.